Domestic pharmaceutical companies have difficult on expanding prescription amount of domestic anticancer treatments

It was identified that domestic pharmaceutical companies have difficult on expanding prescription amount of domestic anticancer treatments due to high entry barrier compared to that of hypertensive treatment or diabetes treatment. In the case of chronic leukemia treatment 'Gleevec', after patent expiration in June last year, 11 domestic companies launched generic drug of Gleevec for about 1 yea...